CVM Message Board Post 8893518 | Cel-Sci Corporation...
home / stock / cvm / cvm message board
bigburt
(investorshub)
Posted on: Apr/10/2023 16:32:52
Source: investorshub
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171650670
Blame Game
News, Short Squeeze, Breakout and More Instantly...
-
Multikine significantly increases overall survival in patients with low levels of tumor cell PD-L1 expression in contrast to approved checkpoint inhibitors 73% survival for Multikine vs 45% in the control arm at 5 years Statistically significant log rank p = 0.0015 ...
-
Dr. Selvaggi was instrumental in the development and approval of lung cancer drugs Zykadia for Novartis and Opdivo for Bristol Myers Squibb CEL-SCI’s Multikine immunotherapy improves the 5-year survival of head and neck cancer patients to 73% compared to 45% in controls and cut...
-
CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended March 31, 2024, as well as key recent clinical and corporate developments. Clinical and Corporate Developments include: In May 2024, CEL-SCI received the go-ahead from the U.S. Food and D...